查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1841936

藥物定序人工智慧的全球市場：市場規模、佔有率和趨勢分析（按組件、技術、最終用途和地區）、按細分市場預測（2025-2033 年）

AI In Drug Repurposing Market Size, Share & Trends Analysis Report By Component, By Technology, By Application, By End Use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

藥物定序人工智慧市場摘要

預計 2024 年全球藥物定序人工智慧市場價值將達到 10.2 億美元，到 2033 年將達到 54.8 億美元，2025 年至 2033 年的複合年成長率為 20.39%。

對具有成本效益的藥物開發的需求不斷成長、人工智慧演算法的進步以及罕見和複雜疾病的日益流行是推動市場成長的主要因素。

此外，製藥公司、學術機構和人工智慧技術供應商之間的合作日益增多，以及運算能力和雲端基礎設施的改進也是推動成長的其他因素。

對具有成本效益的藥物開發策略日益成長的需求是人工智慧在藥物定序發展的主要驅動力。傳統藥物研發需要超過 10 年的漫長時間，每種藥物的成本通常超過 20 億美元。藥物再利用提供了一種策略，透過專注於已已通過核准或正在進行新適應症臨床實驗的藥物來避免早期安全性測試。人工智慧透過快速分析大量生物、化學和臨床資料集並識別新的藥物-疾病關係來加速這一過程。這縮短了開發時間和成本，為製藥公司和醫療保健提供者提供了一種經濟可行的新藥開發替代方案。將人工智慧與藥物再利用相結合可以有效應對關鍵的行業挑戰，提高生產力，同時降低相關風險和投資。

人工智慧系統將多體學數據（包括基因組學、蛋白質組學和代謝體學）與生物醫學文獻和實際患者記錄相結合，以識別以前未被認知的微妙的藥物-標靶相互作用。這些方法能夠識別多藥理學候選藥物和協同藥物組合，克服了傳統基於假設的發現的限制。例如，2025 年 4 月，Plex Research 與 Ginkgo Bioworks 合作，對 GDPx2 資料集進行人工智慧輔助分析，這是一項關於化合物基因表現的大規模轉錄組學研究。此次合作旨在加速識別新的疾病機制、發現新的治療應用以及重新利用藥物。研究結果將與實驗數據相關聯並經過嚴格檢驗。

此外，罕見疾病的日益普及也進一步推動了市場的成長。例如，根據《採血針2024年3月發布的數據，全球將有約3億人罹患罕見疾病，約佔全球人口的3.5%至5.9%。此外，約80%的罕見疾病是遺傳性疾病，其中近70%在兒童時期發病。人工智慧可以促進對罕見疾病患者群體有限資料集的分析，並從現有藥物中識別候選治療方案，從而加速治療的可及性。

目錄

第1章 分析方法與範圍

第2章執行摘要

第3章：人工智慧藥物定序市場：促進因素、趨勢與範圍

  • 市場聯動展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
    • 市場機會分析
    • 市場問題分析
  • 藥物定序人工智慧市場：分析工具
    • 產業分析：波特五力分析
    • PESTEL分析
  • 案例研究
  • 技術分析：關鍵用例和應用領域
    • 機器學習（ML）/深度學習
    • 自然語言處理（NLP）
    • 生成式人工智慧和大規模語言模型（LLM）

第4章：藥物定序人工智慧市場：按組成部分的估計和趨勢分析

  • 細分儀表板
  • 藥物定序人工智慧市場：各成分波動分析
  • 藥物定序人工智慧市場：市場規模預測與各組成部分趨勢分析（2021-2033）
  • 軟體平台
  • 服務

第5章：藥物定序人工智慧市場：依技術估算與趨勢分析

  • 細分儀表板
  • 藥物定序的人工智慧市場：技術變化分析
  • 藥物定序人工智慧：市場規模預測與技術趨勢分析（2021-2033）
  • 機器學習/深度學習
  • 自然語言處理（NLP）
  • 知識圖譜和基於網路的人工智慧
  • 生成式人工智慧和大規模語言模型（LLM）
  • 電腦視覺

第6章：藥物定序人工智慧市場：按應用估算與趨勢分析

  • 細分儀表板
  • 藥物定序人工智慧市場：應用變化分析
  • 藥物定序人工智慧市場：按應用分類的市場規模預測與趨勢分析（2021-2033）
  • 瘤
  • 神經系統疾病
  • 心臟病
  • 感染疾病
  • 罕見疾病
  • 其他治療領域

第7章：人工智慧藥物定序市場：按最終用途的估計和趨勢分析

  • 細分儀表板
  • 藥物定序市場的人工智慧：按最終用途進行的變化分析
  • 藥物定序人工智慧市場：按最終用途分類的市場規模預測和趨勢分析（2021-2033 年）
  • 製藥和生物技術公司
  • CRO（委外研發機構）
  • 學術和研究機構
  • 其他

第 8 章：藥物定序人工智慧市場：區域估計與趨勢分析

  • 各地區市佔率（2024 年及 2033 年）
  • 市場儀表板：按地區
  • 市場規模預測及趨勢分析（2021-2033）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭態勢

  • 公司/競爭對手分類
  • 戰略地圖
  • 企業市場分析（2024年）
  • 公司簡介/上市公司
    • BostonGene Corporation
    • Ginkgo Bioworks
    • IBM
    • TxGNN
    • BioXcel Therapeutics Inc.
    • BullFrog AI Holdings, Inc.
    • Ignota Labs
    • ISOMORPHIC LABS
    • Insilico Medicine
    • Healx
Product Code: GVR-4-68040-755-3

AI In Drug Repurposing Market Summary

The global AI in drug repurposing market size was estimated at USD 1.02 billion in 2024 and is projected to reach USD 5.48 billion by 2033, growing at a CAGR of 20.39% from 2025 to 2033. Rising demand for cost-effective drug development, advancements in AI algorithms, and the growing prevalence of rare and complex diseases are significant factors contributing to market growth.

In addition, increasing collaborations between pharmaceutical companies, academic institutions, and AI technology providers, and improvements in computing power and cloud infrastructure are some other factors fueling the growth.

The rising demand for cost-effective drug development strategies substantially drives the growth of the AI in drug repurposing industry. Traditional drug discovery involves lengthy timelines, often exceeding a decade, and costs frequently exceed USD 2 billion per drug. Drug repurposing offers a strategy to bypass early-stage safety testing by focusing on approved or investigational drugs for new indications. AI accelerates this process by rapidly analyzing extensive biological, chemical, and clinical datasets to identify novel drug-disease associations. This reduces development timelines and costs, offering pharmaceutical companies and healthcare providers an economically viable alternative to de novo drug development. Integrating artificial intelligence with drug repurposing effectively addresses key industry challenges by enhancing productivity while reducing associated risks and investments.

AI systems integrate multi-omics data, including genomics, proteomics, and metabolomics, with biomedical literature and real-world patient records to identify subtle and previously unrecognized drug-target interactions. These methods enable the identification of polypharmacology candidates and synergistic drug combinations, overcoming limitations of traditional hypothesis-driven discovery. For instance, in April 2025, Plex Research partnered with Ginkgo Bioworks to use AI-powered analysis on the GDPx2 dataset, a large transcriptomics survey of compound-induced gene expression. This collaboration aims to identify novel disease mechanisms, discover new therapeutic applications, and accelerate drug repurposing, linking findings with experimental data for rigorous validation.

Furthermore, the rising prevalence of rare diseases propels market growth further. For instance, according to the data published by The Lancet Journal in March 2024, around 300 million people live with rare diseases, affecting around 3.5% - 5.9% of the global population. Moreover, around 80% of rare diseases are genetically caused, almost 70% of which are present in childhood. AI facilitates the analysis of limited datasets from rare disease cohorts, enabling the identification of therapeutic candidates from existing drugs, thus expediting treatment access.

Global AI In Drug Repurposing Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global AI in drug repurposing market report based on component, technology, application, end use, and region:

  • Component Outlook (Revenue, USD Million, 2021 - 2033)
  • Software & Platforms
  • Services
  • Technology Outlook (Revenue, USD Million, 2021 - 2033)
  • Machine Learning/Deep Learning
  • Natural Language Processing (NLP)
  • Knowledge Graphs & Network-Based AI
  • Generative AI & Large Language Models (LLMs)
  • Computer Vision
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Oncology
  • Neurology
  • Cardiology
  • Infectious Diseases
  • Rare & Orphan Diseases
  • Other Therapeutic Areas
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Academic & Research Institutes
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • MEA
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
    • 1.2.1. Component Segment
    • 1.2.2. Technology Segment
    • 1.2.3. Application Segment
    • 1.2.4. End Use
  • 1.3. Information analysis
    • 1.3.1. Market formulation & data visualization
  • 1.4. Data validation & publishing
  • 1.5. Information Procurement
    • 1.5.1. Primary Research
  • 1.6. Information or Data Analysis
  • 1.7. Market Formulation & Validation
  • 1.8. Market Model
  • 1.9. Total Market: CAGR Calculation
  • 1.10. Objectives
    • 1.10.1. Objective 1
    • 1.10.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Insights Landscape

Chapter 3. AI in Drug Repurposing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising demand for cost-effective drug development,
      • 3.2.1.2. Advancements in AI algorithms
      • 3.2.1.3. Increasing collaborations between pharmaceutical companies, academic institutions, and AI technology providers,
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Data security and privacy concerns
      • 3.2.2.2. High computational costs and infrastructure requirements
    • 3.2.3. Market opportunity analysis
    • 3.2.4. Market challenges analysis
  • 3.3. AI in Drug Repurposing Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
      • 3.3.2.4. Environmental Landscape
      • 3.3.2.5. Legal Landscape
      • 3.3.2.6. Social Landscape
  • 3.4. Case Studies
  • 3.5. Technology Analysis: Key Use Cases and Application
    • 3.5.1. Machine Learning (ML)/Deep Learning
    • 3.5.2. Natural Language Processing (NLP)
    • 3.5.3. Generative AI & Large Language Models (LLMs)

Chapter 4. AI in Drug Repurposing Market: Component Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global AI in Drug Repurposing Market Component Movement Analysis
  • 4.3. Global AI in Drug Repurposing Market Size & Trend Analysis, by Component, 2021 to 2033 (USD Million)
  • 4.4. Software & Platforms
    • 4.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 4.5. Services
    • 4.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 5. AI in Drug Repurposing Market: Technology Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global AI in Drug Repurposing Market Technology Movement Analysis
  • 5.3. Global AI in Drug Repurposing Market Size & Trend Analysis, by Technology, 2021 to 2033 (USD Million)
  • 5.4. Machine Learning/Deep Learning
    • 5.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 5.5. Natural Language Processing (NLP)
    • 5.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 5.6. Knowledge Graphs & Network-Based AI
    • 5.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 5.7. Generative AI & Large Language Models (LLMs)
    • 5.7.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 5.8. Computer Vision
    • 5.8.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 6. AI in Drug Repurposing Market: Application Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global AI in Drug Repurposing Market Application Movement Analysis
  • 6.3. Global AI in Drug Repurposing Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
  • 6.4. Oncology
    • 6.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.5. Neurology
    • 6.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.6. Cardiology
    • 6.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.7. Infectious Diseases
    • 6.7.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.8. Rare & Orphan Diseases
    • 6.8.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 6.9. Other Therapeutic Areas
    • 6.9.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 7. AI in Drug Repurposing Market: End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global AI in Drug Repurposing Market End Use Movement Analysis
  • 7.3. Global AI in Drug Repurposing Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 7.4. Pharmaceutical & Biotechnology Companies
    • 7.4.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.5. Contract Research Organizations (CROs)
    • 7.5.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.6. Academic & Research Institutes
    • 7.6.1. Market estimates and forecasts, 2021 to 2033 (USD Million)
  • 7.7. Others
    • 7.7.1. Market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 8. AI in Drug Repurposing Market: Regional Estimates & Trend Analysis

  • 8.1. Regional Market Share Analysis, 2024 & 2033
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 8.4. North America
    • 8.4.1. U.S.
      • 8.4.1.1. Key country dynamics
      • 8.4.1.2. Regulatory framework
      • 8.4.1.3. Competitive scenario
      • 8.4.1.4. U.S. market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.4.2. Canada
      • 8.4.2.1. Key country dynamics
      • 8.4.2.2. Regulatory framework
      • 8.4.2.3. Competitive scenario
      • 8.4.2.4. Canada market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.4.3. Mexico
      • 8.4.3.1. Key country dynamics
      • 8.4.3.2. Regulatory framework
      • 8.4.3.3. Competitive scenario
      • 8.4.3.4. Mexico market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.5. Europe
    • 8.5.1. UK
      • 8.5.1.1. Key country dynamics
      • 8.5.1.2. Regulatory framework
      • 8.5.1.3. Competitive scenario
      • 8.5.1.4. UK market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.5.2. Germany
      • 8.5.2.1. Key country dynamics
      • 8.5.2.2. Regulatory framework
      • 8.5.2.3. Competitive scenario
      • 8.5.2.4. Germany market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.5.3. France
      • 8.5.3.1. Key country dynamics
      • 8.5.3.2. Regulatory framework
      • 8.5.3.3. Competitive scenario
      • 8.5.3.4. France market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.5.4. Italy
      • 8.5.4.1. Key country dynamics
      • 8.5.4.2. Regulatory framework
      • 8.5.4.3. Competitive scenario
      • 8.5.4.4. Italy market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.5.5. Spain
      • 8.5.5.1. Key country dynamics
      • 8.5.5.2. Regulatory framework
      • 8.5.5.3. Competitive scenario
      • 8.5.5.4. Spain market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.5.6. Norway
      • 8.5.6.1. Key country dynamics
      • 8.5.6.2. Regulatory framework
      • 8.5.6.3. Competitive scenario
      • 8.5.6.4. Norway market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.5.7. Sweden
      • 8.5.7.1. Key country dynamics
      • 8.5.7.2. Regulatory framework
      • 8.5.7.3. Competitive scenario
      • 8.5.7.4. Sweden market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.5.8. Denmark
      • 8.5.8.1. Key country dynamics
      • 8.5.8.2. Regulatory framework
      • 8.5.8.3. Competitive scenario
      • 8.5.8.4. Denmark market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Japan
      • 8.6.1.1. Key country dynamics
      • 8.6.1.2. Regulatory framework
      • 8.6.1.3. Competitive scenario
      • 8.6.1.4. Japan market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.2. China
      • 8.6.2.1. Key country dynamics
      • 8.6.2.2. Regulatory framework
      • 8.6.2.3. Competitive scenario
      • 8.6.2.4. China market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.3. India
      • 8.6.3.1. Key country dynamics
      • 8.6.3.2. Regulatory framework
      • 8.6.3.3. Competitive scenario
      • 8.6.3.4. India market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.4. Australia
      • 8.6.4.1. Key country dynamics
      • 8.6.4.2. Regulatory framework
      • 8.6.4.3. Competitive scenario
      • 8.6.4.4. Australia market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.5. South Korea
      • 8.6.5.1. Key country dynamics
      • 8.6.5.2. Regulatory framework
      • 8.6.5.3. Competitive scenario
      • 8.6.5.4. South Korea market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.6.6. Thailand
      • 8.6.6.1. Key country dynamics
      • 8.6.6.2. Regulatory framework
      • 8.6.6.3. Competitive scenario
      • 8.6.6.4. Thailand market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Brazil
      • 8.7.1.1. Key country dynamics
      • 8.7.1.2. Regulatory framework
      • 8.7.1.3. Competitive scenario
      • 8.7.1.4. Brazil market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.7.2. Argentina
      • 8.7.2.1. Key country dynamics
      • 8.7.2.2. Regulatory framework
      • 8.7.2.3. Competitive scenario
      • 8.7.2.4. Argentina market estimates and forecasts, 2021 to 2033 (USD Million)
  • 8.8. MEA
    • 8.8.1. South Africa
      • 8.8.1.1. Key country dynamics
      • 8.8.1.2. Regulatory framework
      • 8.8.1.3. Competitive scenario
      • 8.8.1.4. South Africa market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.8.2. Saudi Arabia
      • 8.8.2.1. Key country dynamics
      • 8.8.2.2. Regulatory framework
      • 8.8.2.3. Competitive scenario
      • 8.8.2.4. Saudi Arabia market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.8.3. UAE
      • 8.8.3.1. Key country dynamics
      • 8.8.3.2. Regulatory framework
      • 8.8.3.3. Competitive scenario
      • 8.8.3.4. UAE market estimates and forecasts, 2021 to 2033 (USD Million)
    • 8.8.4. Kuwait
      • 8.8.4.1. Key country dynamics
      • 8.8.4.2. Regulatory framework
      • 8.8.4.3. Competitive scenario
      • 8.8.4.4. Kuwait market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company/Competition Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Market Position Analysis, 2024
  • 9.4. Company Profiles/Listing
    • 9.4.1. BostonGene Corporation
      • 9.4.1.1. Company overview
      • 9.4.1.2. Financial performance
      • 9.4.1.3. Product benchmarking
      • 9.4.1.4. Strategic initiatives
    • 9.4.2. Ginkgo Bioworks
      • 9.4.2.1. Company overview
      • 9.4.2.2. Financial performance
      • 9.4.2.3. Product benchmarking
      • 9.4.2.4. Strategic initiatives
    • 9.4.3. IBM
      • 9.4.3.1. Company overview
      • 9.4.3.2. Financial performance
      • 9.4.3.3. Product benchmarking
      • 9.4.3.4. Strategic initiatives
    • 9.4.4. TxGNN
      • 9.4.4.1. Company overview
      • 9.4.4.2. Financial performance
      • 9.4.4.3. Product benchmarking
      • 9.4.4.4. Strategic initiatives
    • 9.4.5. BioXcel Therapeutics Inc.
      • 9.4.5.1. Company overview
      • 9.4.5.2. Financial performance
      • 9.4.5.3. Product benchmarking
      • 9.4.5.4. Strategic initiatives
    • 9.4.6. BullFrog AI Holdings, Inc.
      • 9.4.6.1. Company overview
      • 9.4.6.2. Financial performance
      • 9.4.6.3. Product benchmarking
      • 9.4.6.4. Strategic initiatives
    • 9.4.7. Ignota Labs
      • 9.4.7.1. Company overview
      • 9.4.7.2. Financial performance
      • 9.4.7.3. Product benchmarking
      • 9.4.7.4. Strategic initiatives
    • 9.4.8. ISOMORPHIC LABS
      • 9.4.8.1. Company overview
      • 9.4.8.2. Financial performance
      • 9.4.8.3. Product benchmarking
      • 9.4.8.4. Strategic initiatives
    • 9.4.9. Insilico Medicine
      • 9.4.9.1. Company overview
      • 9.4.9.2. Financial performance
      • 9.4.9.3. Product benchmarking
      • 9.4.9.4. Strategic initiatives
    • 9.4.10. Healx
      • 9.4.10.1. Company overview
      • 9.4.10.2. Financial performance
      • 9.4.10.3. Product benchmarking
      • 9.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global AI in drug repurposing market, by region, 2021 - 2033 (USD Million)
  • Table 3 Global AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 4 Global AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 5 Global AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 6 Global AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 7 North America AI in drug repurposing market, by country, 2021 - 2033 (USD Million)
  • Table 8 North America AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 9 North America AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 10 North America AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 11 North America AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 12 U.S. AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 13 U.S. AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 14 U.S. AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 15 U.S. AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 16 Canada AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 17 Canada AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 18 Canada AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 19 Canada AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 20 Mexico AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 21 Mexico AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 22 Mexico AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 23 Mexico AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 24 Europe AI in drug repurposing market, by country, 2021 - 2033 (USD Million)
  • Table 25 Europe AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 26 Europe AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 27 Europe AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 28 Europe AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 29 UK AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 30 UK AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 31 UK AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 32 UK AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 33 Germany AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 34 Germany AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 35 Germany AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 36 Germany AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 37 France AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 38 France AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 39 France AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 40 France AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 41 Italy AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 42 Italy AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 43 Italy AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 44 Italy AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 45 Spain AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 46 Spain AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 47 Spain AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 48 Spain AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 49 Denmark AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 50 Denmark AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 51 Denmark AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 52 Denmark AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 53 Sweden AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 54 Sweden AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 55 Sweden AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 56 Sweden AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 57 Norway AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 58 Norway AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 59 Norway AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 60 Norway AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 61 Asia Pacific AI in drug repurposing market, by country, 2021 - 2033 (USD Million)
  • Table 62 Asia Pacific AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 63 Asia Pacific AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 64 Asia Pacific AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 65 Asia Pacific AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 66 China AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 67 China AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 68 China AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 69 China AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 70 Japan AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 71 Japan AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 72 Japan AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 73 Japan AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 74 India AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 75 India AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 76 India AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 77 India AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 78 South Korea AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 79 South Korea AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 80 South Korea AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 81 South Korea AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 82 Australia AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 83 Australia AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 84 Australia AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 85 Australia AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 86 Thailand AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 87 Thailand AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 88 Thailand AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 89 Thailand AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 90 Latin America AI in drug repurposing market, by country, 2021 - 2033 (USD Million)
  • Table 91 Latin America AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 92 Latin America AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 93 Latin America AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 94 Latin America AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 95 Brazil AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 96 Brazil AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 97 Brazil AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 98 Brazil AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 99 Argentina AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 100 Argentina AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 101 Argentina AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 102 Argentina AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 103 MEA AI in drug repurposing market, by country, 2021 - 2033 (USD Million)
  • Table 104 MEA AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 105 MEA AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 106 MEA AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 107 MEA AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 108 South Africa AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 109 South Africa AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 110 South Africa AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 111 South Africa AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 112 Saudi Arabia AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 113 Saudi Arabia AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 114 Saudi Arabia AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 115 Saudi Arabia AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 116 UAE AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 117 UAE AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 118 UAE AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 119 UAE AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)
  • Table 120 Kuwait AI in drug repurposing market, by component, 2021 - 2033 (USD Million)
  • Table 121 Kuwait AI in drug repurposing market, by application, 2021 - 2033 (USD Million)
  • Table 122 Kuwait AI in drug repurposing market, by technology, 2021 - 2033 (USD Million)
  • Table 123 Kuwait AI in drug repurposing market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Market formulation & validation
  • Fig. 5 AI in drug repurposing market: Market outlook
  • Fig. 6 AI in drug repurposing market: Segment outlook
  • Fig. 7 AI in drug repurposing market: Competitive landscape outlook
  • Fig. 8 Parent market outlook
  • Fig. 9 AI in drug repurposing market driver impact
  • Fig. 10 AI in drug repurposing market restraint impact
  • Fig. 11 AI in drug repurposing market: Component outlook and key takeaways
  • Fig. 12 AI in drug repurposing market: Component movement analysis
  • Fig. 13 Software & platform market estimates and forecasts,2021 - 2033 (USD Million)
  • Fig. 14 Services market estimates and forecasts,2021 - 2033 (USD Million)
  • Fig. 15 AI in drug repurposing market: Technology outlook and key takeaways
  • Fig. 16 AI in drug repurposing market: Technology movement analysis
  • Fig. 17 Machine learning/deep learning market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 18 Natural language processing (NLP) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 19 Knowledge graphs & network-based AI market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 20 Generative AI & large language models (LLMs) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 21 Computer vision market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 AI in drug repurposing market: Application outlook and key takeaways
  • Fig. 23 AI in drug repurposing market: Application movement analysis
  • Fig. 24 Oncology market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Neurology market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Cardiology market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Infectious diseases market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 Rare & orphan diseases market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 Other therapeutic areas market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 AI in drug repurposing market: End use outlook and key takeaways
  • Fig. 31 AI in drug repurposing market: End use movement analysis
  • Fig. 32 Pharmaceutical & biotechnology companies market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Contract research organizations (CROs) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Academic & research institutes market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Global AI in drug repurposing market: Regional outlook and key takeaways
  • Fig. 37 Global AI in drug repurposing market: Regional movement analysis
  • Fig. 38 North America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 U.S. key country dynamics
  • Fig. 40 U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Canada key country dynamics
  • Fig. 42 Canada market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 Mexico key country dynamics
  • Fig. 44 Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 Europe market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 UK key country dynamics
  • Fig. 47 UK market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Germany key country dynamics
  • Fig. 49 Germany market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 France key country dynamics
  • Fig. 51 France market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Italy key country dynamics
  • Fig. 53 Italy market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 Spain key country dynamics
  • Fig. 55 Spain market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 Denmark key country dynamics
  • Fig. 57 Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 Sweden key country dynamics
  • Fig. 59 Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 Norway key country dynamics
  • Fig. 61 Norway market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 Asia Pacific market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Japan key country dynamics
  • Fig. 64 Japan market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 China key country dynamics
  • Fig. 66 China market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 India key country dynamics
  • Fig. 68 India market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 Thailand key country dynamics
  • Fig. 70 Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 71 South Korea key country dynamics
  • Fig. 72 South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 73 Australia key country dynamics
  • Fig. 74 Australia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 75 Latin America market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 Brazil key country dynamics
  • Fig. 77 Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 78 Argentina key country dynamics
  • Fig. 79 Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 80 Middle East and Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 81 South Africa key country dynamics
  • Fig. 82 South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 83 Saudi Arabia key country dynamics
  • Fig. 84 Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 85 UAE key country dynamics
  • Fig. 86 UAE market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 87 Kuwait key country dynamics
  • Fig. 88 Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)